Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet

Abstract

Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease. C57BL/6 mice were fed either the control diet, 60% fat diet with 30% fructose water (HFFD), or HFFD with spironolactone for 8 wk. HFFD mice demonstrated apparent phenotypes of metabolic syndrome, including insulin resistance, hypertension, dyslipidemia, and fatty liver. Although treatment with spironolactone did not affect the increased calorie intake and body weight by HFFD, the increments of epididymal fat weight, blood pressure, serum triglyceride, free fatty acids, leptin, and total cholesterol levels were significantly suppressed. Elevation of blood glucose during glucose and insulin tolerance tests in HFFD mice was significantly lowered by spironolactone. Notably, increased glucose levels during pyruvate tolerance test in HFFD mice were almost completely ameliorated to control levels by the treatment. Staining with hematoxylin-eosin (HE) and Oil-red-O demonstrated marked accumulation of triglycerides in the centrilobular part of the hepatic lobule in HFFD mice, and these accumulations were effectively improved by spironolactone. Concomitantly HFFD feeding markedly up-regulated hepatic mRNA expression of proinflammatory cytokines (TNFα, IL-6, and monocyte chemoattractant protein-1), gluconeogenic gene phosphoenolpyruvate carboxykinase, transcription factor carbohydrate response element binding protein, and its downstream lipogenic enzymes, all of which were significantly suppressed by spironolactone. These results indicate that inhibition of mineralocorticoid receptor might be a beneficial therapeutic approach for diet-induced phenotypes of metabolic syndrome and fatty liver.

Overview

Integrity signals

Registry

Crossref · 10.1210/en.2009-0869

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 44 references

Cited by

See all 189

Metadata

Authors
Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., & Sasaoka, T.
Affiliations
  • University of Toyama (JP)
  • Kanazawa Medical University (JP)
Corresponding author
Sasaoka, Toshiyasu
Venue
Endocrinology
Published
2010-03-08
Volume
151
Issue
5
Pages
2040-2049
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2097868433
Cited by
189
References
44
Citations by year
2026: 4 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 15 · 2021: 16 · 2020: 14 · 2019: 18 · 2018: 14 · 2017: 10 · 2016: 10 · 2015: 16 · 2014: 10 · 2013: 20 · 2012: 11
FWCI
9.77
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Toyama
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
spironolactone, mineralocorticoid receptor antagonism, non-alcoholic fatty liver disease, hepatic steatosis, glucose metabolism, lipid metabolism, metabolic syndrome, insulin resistance, high-fat high-fructose diet, gluconeogenesis, liver inflammation, inflammatory cytokines, ChREBP, dyslipidemia
MeSH terms
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Mineralocorticoid Receptor Antagonists, Animals, Body Weight, Cells, Cultured, Dietary Carbohydrates, Dietary Fats, Fatty Liver, Gluconeogenesis, Glucose, Humans, Inflammation, Insulin, Lipids, Male, Mice, Inbred C57BL, Spironolactone, Transcription Factors, Trans-Activators, Gene Expression, Rats, Sprague-Dawley, Reverse Transcriptase Polymerase Chain Reaction, Lipid Metabolism, Mice, Rats, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet. https://app.cochat.ai/papers/10.1210/en.2009-0869
The paper
Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., & Sasaoka, T. (2010). Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet. Endocrinology. https://doi.org/10.1210/en.2009-0869

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.